Hernández y HH

Idioma: Español
Referencias bibliográficas: 20
Paginas: 3-4
Archivo PDF: 53.23 Kb.

FRAGMENTO

La alta prevalencia de hipertensión y diabetes mellitus en nuestro país, 30.05 y 10.9% respectivamente,1 la frecuente asociación de diabetes en el hipertenso, 16.4% en población abierta y 18.8% en la consulta privada,1,2 así como la alta morbilidad y mortalidad que ocasionan, nos obligan a estar siempre actualizando nuestra información.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Velázquez MO, Rosas PM, Lara EA, Pastelín HG, Grupo ENSA 2000; Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA). Arch Cardiol Mex 2000; 72: 71-84

2. Hernández HH, Brito O, Domínguez A, Luengas ME y cols. Prevalencia de factores de riesgo coronario en pacientes hipertensos. Rev Mex Cardiol 1999; 10(3): 112-117.

3. UK Prospective Diabetes Study Group. High blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. Br Med J 1998; 317: 703-713.

4. Hansson L, Zanchetti A, Carruthers SG et al. For the HOT Study Group: Effects of intensive blood pressure lowering and low-dose aspirin in patients with Hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

5. Asociación Latinoamericana de Diabetes. Guías ALAD 2000. Para el diagnóstico y manejo de la Diabetes Mellitus tipo 2, con medicina basada en evidencia. Capítulo 14.

6. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-650.

7. Tatti P, Pabor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-601.

8. Birkenhäger WH, Staessen JA. Treatment of Diabetic Patients with Hypertension. Current Hypertension Reports 1999; 3: 225-231.

9. Crepaldi G, Carta Q, Deferrari G et al. Effects of lisinopril and nifedipino on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-110.

10. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with once-daily calcium channel blockade or diuretic in the International Nifedipine GITS Study; Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-342.

11. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact f 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103: 2579-2584.

12. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM. Outcomes With Nifedipine GITS or Co-AMilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.

13. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid- lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

14. Brown MJ. Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. Br J Diabetes Vasc Dis 2003; 3: 245-251.

15. de Pablos VPL, Martínez MFJ. Effects of Losartan and Dilitiazem on Blood Pressure, Insulin Sensitivity, Lipid Profile and Microalbuminuria in Hypertensive Type 2 Diabetic Patients. Clin Drug Invest 1998; 16(5): 361-370.

16. Ruilope LM. Long-term Protection in At-risk Hypertensive Patients. A Role for Nifedipine GITS? Blood Pressure 2002; 11: 106-109.

17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.

18. 2003 European Society of Hypertension – European Society of Cardiology. Guidelines for the Management of Arterial Hypertension. J Hypertens 2003; 21: 1011-1053.

19. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: S80-S82.

20. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.